These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 38728911)
1. Design, synthesis and biological evaluation of new RNF126-based p300/CBP degraders. Lei YH; Tang Q; Ni Y; Li CH; Luo P; Huang K; Chen X; Zhu YX; Wang NY Bioorg Chem; 2024 Jul; 148():107427. PubMed ID: 38728911 [TBL] [Abstract][Full Text] [Related]
2. Discovery of Highly Potent and Efficient CBP/p300 Degraders with Strong Hu J; Xu H; Wu T; Zhang C; Shen H; Dong R; Hu Q; Xiang Q; Chai S; Luo G; Chen X; Huang Y; Zhao X; Peng C; Wu X; Lin B; Zhang Y; Xu Y J Med Chem; 2024 May; 67(9):6952-6986. PubMed ID: 38649304 [TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and biological evaluation of a novel spiro oxazolidinedione as potent p300/CBP HAT inhibitor for the treatment of ovarian cancer. Ding H; Pei Y; Li Y; Xu W; Mei L; Hou Z; Guang Y; Cao L; Li P; Cao H; Bian J; Chen K; Luo C; Zhou B; Zhang T; Li Z; Yang Y Bioorg Med Chem; 2021 Dec; 52():116512. PubMed ID: 34801827 [TBL] [Abstract][Full Text] [Related]
4. Discovery of a Promising CBP/p300 Degrader XYD129 for the Treatment of Acute Myeloid Leukemia. Wu T; Hu J; Zhao X; Zhang C; Dong R; Hu Q; Xu H; Shen H; Zhang X; Zhang Y; Lin B; Wu X; Xiang Q; Xu Y J Med Chem; 2024 Jun; 67(11):9194-9213. PubMed ID: 38829718 [TBL] [Abstract][Full Text] [Related]
5. Discovery, Structure-Activity Relationship, and Biological Activity of Histone-Competitive Inhibitors of Histone Acetyltransferases P300/CBP. Wu F; Hua Y; Kaochar S; Nie S; Lin YL; Yao Y; Wu J; Wu X; Fu X; Schiff R; Davis CM; Robertson M; Ehli EA; Coarfa C; Mitsiades N; Song Y J Med Chem; 2020 May; 63(9):4716-4731. PubMed ID: 32314924 [TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and biological evaluation of a new class of histone acetyltransferase p300 inhibitors. Liu R; Zhang Z; Yang H; Zhou K; Geng M; Zhou W; Zhang M; Huang X; Li Y Eur J Med Chem; 2019 Oct; 180():171-190. PubMed ID: 31306905 [TBL] [Abstract][Full Text] [Related]
7. Discovery and biological evaluation of thiobarbituric derivatives as potent p300/CBP inhibitors. Lu W; Xiong H; Chen Y; Wang C; Zhang H; Xu P; Han J; Xiao S; Ding H; Chen Z; Lu T; Wang J; Zhang Y; Yue L; Liu YC; Zhang C; Yang Y; Jiang H; Chen K; Zhou B; Luo C Bioorg Med Chem; 2018 Nov; 26(20):5397-5407. PubMed ID: 30297119 [TBL] [Abstract][Full Text] [Related]
8. Discovery of Novel PROTAC Degraders of p300/CBP as Potential Therapeutics for Hepatocellular Carcinoma. Chang Q; Li J; Deng Y; Zhou R; Wang B; Wang Y; Zhang M; Huang X; Li Y J Med Chem; 2024 Feb; 67(4):2466-2486. PubMed ID: 38316017 [TBL] [Abstract][Full Text] [Related]
9. Discovery of Exceptionally Potent, Selective, and Efficacious PROTAC Degraders of CBP and p300 Proteins. Thomas JE; Wang M; Jiang W; Wang M; Wang L; Wen B; Sun D; Wang S J Med Chem; 2023 Jun; 66(12):8178-8199. PubMed ID: 37276143 [TBL] [Abstract][Full Text] [Related]
10. Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours. Lasko LM; Jakob CG; Edalji RP; Qiu W; Montgomery D; Digiammarino EL; Hansen TM; Risi RM; Frey R; Manaves V; Shaw B; Algire M; Hessler P; Lam LT; Uziel T; Faivre E; Ferguson D; Buchanan FG; Martin RL; Torrent M; Chiang GG; Karukurichi K; Langston JW; Weinert BT; Choudhary C; de Vries P; Van Drie JH; McElligott D; Kesicki E; Marmorstein R; Sun C; Cole PA; Rosenberg SH; Michaelides MR; Lai A; Bromberg KD Nature; 2017 Oct; 550(7674):128-132. PubMed ID: 28953875 [TBL] [Abstract][Full Text] [Related]
11. An inhibitor of the acetyltransferases CBP/p300 exerts antineoplastic effects on gastrointestinal stromal tumor cells. Gu ML; Wang YM; Zhou XX; Yao HP; Zheng S; Xiang Z; Ji F Oncol Rep; 2016 Nov; 36(5):2763-2770. PubMed ID: 27633918 [TBL] [Abstract][Full Text] [Related]
12. Discovery of IAP-recruiting BCL-X Zhang X; He Y; Zhang P; Budamagunta V; Lv D; Thummuri D; Yang Y; Pei J; Yuan Y; Zhou D; Zheng G Eur J Med Chem; 2020 Aug; 199():112397. PubMed ID: 32388279 [TBL] [Abstract][Full Text] [Related]
13. Targeting CBP and p300: Emerging Anticancer Agents. Masci D; Puxeddu M; Silvestri R; La Regina G Molecules; 2024 Sep; 29(19):. PubMed ID: 39407454 [TBL] [Abstract][Full Text] [Related]
14. CN470 is a BET/CBP/p300 multi-bromodomain inhibitor and has an anti-tumor activity against MLL-rearranged acute lymphoblastic leukemia. Imayoshi N; Yoshioka M; Tanaka K; Yang SM; Akahane K; Toda Y; Hosogi S; Inukai T; Okada S; Maloney DJ; Nakahata T; Takita J; Kato I; Ashihara E Biochem Biophys Res Commun; 2022 Jan; 590():49-54. PubMed ID: 34971957 [TBL] [Abstract][Full Text] [Related]
15. Discovery of a Potent and Selective in Vivo Probe (GNE-272) for the Bromodomains of CBP/EP300. Crawford TD; Romero FA; Lai KW; Tsui V; Taylor AM; de Leon Boenig G; Noland CL; Murray J; Ly J; Choo EF; Hunsaker TL; Chan EW; Merchant M; Kharbanda S; Gascoigne KE; Kaufman S; Beresini MH; Liao J; Liu W; Chen KX; Chen Z; Conery AR; Côté A; Jayaram H; Jiang Y; Kiefer JR; Kleinheinz T; Li Y; Maher J; Pardo E; Poy F; Spillane KL; Wang F; Wang J; Wei X; Xu Z; Xu Z; Yen I; Zawadzke L; Zhu X; Bellon S; Cummings R; Cochran AG; Albrecht BK; Magnuson S J Med Chem; 2016 Dec; 59(23):10549-10563. PubMed ID: 27682507 [TBL] [Abstract][Full Text] [Related]
16. Small-molecule inhibitors of acetyltransferase p300 identified by high-throughput screening are potent anticancer agents. Yang H; Pinello CE; Luo J; Li D; Wang Y; Zhao LY; Jahn SC; Saldanha SA; Chase P; Planck J; Geary KR; Ma H; Law BK; Roush WR; Hodder P; Liao D Mol Cancer Ther; 2013 May; 12(5):610-20. PubMed ID: 23625935 [TBL] [Abstract][Full Text] [Related]
17. Inhibition of the acetyltransferases p300 and CBP reveals a targetable function for p300 in the survival and invasion pathways of prostate cancer cell lines. Santer FR; Höschele PP; Oh SJ; Erb HH; Bouchal J; Cavarretta IT; Parson W; Meyers DJ; Cole PA; Culig Z Mol Cancer Ther; 2011 Sep; 10(9):1644-55. PubMed ID: 21709130 [TBL] [Abstract][Full Text] [Related]
18. Exploration of bromodomain ligand-linker conjugation sites for efficient CBP/p300 heterobifunctional degrader activity. Kumar Tiwari P; Reddy Doda S; Vannam R; Hudlikar M; Harrison DA; Ojeda S; Rai S; Koglin AS; Nguyen Gilbert A; Ott CJ Bioorg Med Chem Lett; 2024 Apr; 102():129676. PubMed ID: 38408512 [TBL] [Abstract][Full Text] [Related]
19. From triazolophthalazines to triazoloquinazolines: A bioisosterism-guided approach toward the identification of novel PCAF inhibitors with potential anticancer activity. El-Shershaby MH; Ghiaty A; Bayoumi AH; Al-Karmalawy AA; Husseiny EM; El-Zoghbi MS; Abulkhair HS Bioorg Med Chem; 2021 Jul; 42():116266. PubMed ID: 34126285 [TBL] [Abstract][Full Text] [Related]
20. Structure-based drug optimization and biological evaluation of tetrahydroquinolin derivatives as selective and potent CBP bromodomain inhibitors. Bi X; Chen Y; Sun Z; Lu W; Xu P; Lu T; Ding H; Zhang N; Jiang H; Chen K; Zhou B; Luo C Bioorg Med Chem Lett; 2020 Nov; 30(22):127480. PubMed ID: 32882416 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]